DDInter9 DDInter1376
To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one prior therapy. In August 2022, the FDA approved a new tablet formulation of Calquence, enabling the co-administration of this drug with proton pump inhibitors (PPIs).[L42795,L42800] Unlike Calquence capsules, the co-administration of Calquence tablets and PPIs does not have an effect in the pharmacokinetics of
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magaldrate
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Acalabrutinib {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Acalabrutinib {u} may lead to a major life threatening interaction when taken with {v} Binimetinib
Acalabrutinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Magaldrate
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Acalabrutinib may lead to a major life threatening interaction when taken with Idelalisib
Acalabrutinib may lead to a major life threatening interaction when taken with Binimetinib
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Acalabrutinib may lead to a major life threatening interaction when taken with Flurbiprofen